R eperfusion therapy with r-tPA (recombinant tissue-type plasminogen activator) or mechanical thrombectomy of large vessels is the standard of care for patients with acute ischemic stroke. Although reperfusion of ischemic region has shown promising clinical outcomes, evidence from several patients and animal models suggest that cerebral reperfusion promotes oxidative stress, secondary thrombosis, and vascular inflammation, which aggravate neuronal death in the ischemic penumbra. 1, 2 There is currently no effective intervention to reduce brain damage after reperfusion. Both thrombosis and inflammation contribute to the pathophysiology of acute ischemic stroke. 3 A better understanding of molecular mechanisms that promote thrombo-inflammatory brain injury may result in novel therapeutic interventions to reduce brain damage after an acute ischemic stroke.
The extracellular matrix protein Fn (fibronectin) is known to contribute to inflammation and thrombosis. [4] [5] [6] Fn exists in multiple isoforms that are generated by alternative processing Background and Purpose-Cellular Fn-EDA (fibronectin containing extra domain A) is expressed in activated endothelial cells and elevated in circulation in patients with cardiovascular diseases. Although global deficiency of Fn-EDA in mice improves stroke outcome, the specific contribution of plasma versus endothelium Fn-EDA in stroke outcome is currently unknown. We investigated the role of plasma versus endothelial Fn-EDA in stroke exacerbation in the comorbid condition of hyperlipidemia. [7] [8] [9] Recently, we have reported that nonhematopoietic cell-derived Fn-EDA mediates ischemia/reperfusion brain injury. 5 Patients with acute ischemic stroke have severe endothelial dysfunction, 10, 11 and reports suggest that endothelial injury results in an increased expression of Fn-EDA. 12, 13 Furthermore, the influx of polymorphonuclear leukocytes at the ischemic site, after reperfusion, elicits a robust inflammatory response and was associated with increased Fn-EDA synthesis by endothelial cells.
Methods-We generated novel plasma
14 These observations prompted us to investigate the relative contribution of plasma versus endothelial Fn-EDA in stroke exacerbation.
Current Stroke Therapy Academic Industry Roundtable criterion for preclinical stroke evolution recommends determining the mechanisms in animal models with comorbidities, including hyperlipidemia, that adequately mimics the human scenario. 15 Therefore, we generated novel plasma Fn-EDA ) background. We provide definitive evidence for the first time that it is Fn-EDA in the plasma and not in the endothelial cells that exacerbates stroke outcome.
Methods
Because of the word limit, a detailed description of the Materials and Methods is present in the online-only Data Supplement. The data that supports the findings of this study are available from the corresponding author on reasonable request.
Animals
Ten-to 12-week-old male and female mice weighing around 20 to 26 g were used in the present study. Fn-EDA fl/fl mice have been described previously. 16 To generate endothelial-specific Fn-EDA deficient mice (ApoE 
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Cre mouse. Controls were littermates. All mice used in the present study were on the C57BL/6J background. The University of Iowa Animal Care and Use Committee approved all the procedures, and studies were performed according to the current Animal Research: Reporting of In vivo Experiment guidelines (https://www.nc3rs.org.uk/arrive-guidelines).
Transient Middle Cerebral Artery Occlusion by Intraluminal Monofilament
Focal cerebral ischemia was achieved by transiently occluding the right middle cerebral artery for 60 minutes as described. 5 Mice were anesthetized with 1% to 1.5% isoflurane mixed with medical air. After a midline incision, the right common carotid artery was temporarily clamped, and a filament (6.0 siliconized) was inserted via the external carotid artery into the internal carotid artery up to the origin of the middle cerebral artery. Reperfusion was achieved by removing the filament after 60 minutes and opening the common carotid artery. Laser Doppler flowmetry (Perimed instruments, Sweden) was used for each mouse to confirm the successful induction of ischemia and reperfusion. Animals having >70% reduction in the regional cerebral blood flow were included in the study.
Embolic Middle Cerebral Artery Occlusion
Fifty microliters of arterial blood from the experimental mice was supplemented with human fibrinogen (2 mg/mL) and clotted in a polyethylene-10 tube for 4 hours at room temperature, followed by storage at 4°C overnight. The polyethylene-10 catheter containing homologous washed fibrin-rich clots (≈20 mm) was then introduced into the internal carotid artery. r-tPA (10 mg/kg, 10% volume by bolus and remaining slow infusion for 30 minutes) was infused via a jugular vein 60 minutes postembolization. Laser Doppler flowmetry was performed to confirm the ischemia and reperfusion.
Magnetic Resonance Imaging and Infarct Volume Quantification
Magnetic resonance imaging was performed on day 1 postreperfusion as per previously described protocol. 17 Briefly, animals were anesthetized with isoflurane (2.5% induction, 1.2% maintenance) and placed in the bore of the 7.0 Tesla MRI (Agilent Technologies, Inc, Santa Clara, CA) with a 2-channel receive-only surface coil. Following scout scans to orient the imaging planes, high-resolution images were acquired with a 9-minute T2-weighted 2-dimensional fast spin-echo pulse sequence oriented coronally. Imaging parameters included repetition time/echo time=6380 ms/83 ms, echo train length of 12, voxel resolution 0.10×0.10×0.50 mm, field of view covering 25.0×18.8×14.0 mm with no gaps, and 7 signal averages. Total imaging time for each animal was ≈20 minutes. The area of infarction was quantified using National Institutes of Health Image J software by outlining the zone with abnormally hyperintense regions in each brain slice, and the total infarct volume was obtained by summation of the infarcted areas multiplied by the slice thickness. To correct for brain swelling due to edema after ischemia, the corrected total infarct volume (%) was calculated. Corrected infarct volume (%)=(volume of contralateral hemisphere−[volume of ipsilateral hemisphere−volume of infarct])/volume of contralateral hemisphere×100.
Statistical Analysis
Results are reported as mean±SEM except for the neurological scores (Bederson score and modified Neurological Severity Score), where the median±range was used. The number of experimental animals in each group was based on power calculations for the primary parameter (infarct volume) with mean differences and standard deviations taken from pilot data at power 80% with an alpha of 0.05. For statistical analysis, GraphPad Prism software, version 7.04 was used. Shapiro-Wilk test was used to check normality and Bartlett test was used to check equal variance. The statistical significance was assessed using either unpaired t test or 1-way ANOVA followed by Holm-Sidak multiple comparisons test (for normally distributed data) and Mann-Whitney test or Kruskal-Wallis test followed by Dunn multiple comparisons test (for not normally distributed data). P<0.05 was considered to be statistically significant. strain, which constitutively expresses Fn-EDA, have a significant decrease in total Fn levels in the plasma and tissues when compared with wild type. 16 Notably, hepatocyte-specific deletion of EDA exon in Fn-EDA fl/fl strain normalizes total Fn levels both in the plasma and tissues. 18 In agreement with these studies, we found that hepatocyte-specific deletion of EDA exon in ApoE , mice exhibit improved stroke outcome. A and C, Left: Representative magnetic resonance imaging from 1 mouse (male and female) of each genotype on day 1. White is the infarct area. Right: Corrected mean infarct volumes of each genotype (N=8-12/group). Data are mean±SEM. Statistical analysis: 1-way ANOVA followed by Holm-Sidak multiple comparisons test. B and D, Neurological outcome of male and female mice from each genotype as assessed before sacrifice on day 1 (depicted as scatter plots including median). ANOVA on ranks was applied to test for significant differences in the neurological score. NS indicates not significant. Figure 2B and 2C). Next, we evaluated the modified Neurological Severity Score which rates neurological functioning based on spontaneous activity, symmetry in the movement of 4 limbs, forepaw outstretching, climbing, body proprioception, and responses to vibrissae touch (on the scale of 3 to 18; higher score indicates a better outcome). 19 We found that ApoE Figure 2D ). Figure 3B and 3C) suggesting that Fn-EDA present in the plasma may promote secondary intracerebral thrombosis, and thereby worsens stroke outcome. After ischemia-reperfusion injury, neutrophils are the first immune cells to respond and also significantly contribute to ischemic brain damage by promoting inflammation. 20, 21 To determine whether improved stroke outcome in ApoE 
Results

Generation and Characterization of Plasma
Lack of Fn-EDA in the Plasma Improves Regional Cerebral Blood Flow and Limits Postischemic Thrombo-Inflammatory Response
Targeting Fn-EDA in the Plasma Improves Stroke Outcome in the Embolic Stroke Model
To determine whether the observed effect is not limited to 1 model, but generalizable to a broader context, we evaluated the role of plasma Fn-EDA in the embolic model of stroke. In this model, homologous washed fibrin-rich clots (≈20 mm) were infused through the internal carotid artery. Laser Doppler flowmetry and laser speckle imaging were performed to confirm ischemia and reperfusion. After 60 minutes of ischemia, r-tPA (10 mg/kg, 10% volume by bolus and remaining slow infusion for 30 minutes) was infused through the jugular vein. We found significantly reduced infarct volume and improved neurological Figure 5D ) suggesting that plasma Fn-EDA promotes postischemic secondary thrombosis and may thereby worsen stroke outcome in an embolic model of stroke. Importantly, coinfusion of specific anti-Fn EDA antibody with r-tPA, 1 hr post embolization, improved stroke outcome and enhanced poststroke survival and improved neurological recovery in the embolic stroke model (P<0.05 versus ApoE −/− mice infused with r-tPA; Figure 6 ). Owing to higher mortality, we could not evaluate long-term functional outcome after r-tPA infusion.
Discussion
Although several interventions have shown efficacy in preclinical stroke models, they have been unsuccessful in the clinics. It is now believed that a critical factor for the lack of translation from bench to bedside is that preclinical evaluation of mechanisms of ischemic stroke progression and therapeutic studies are typically done in healthy animals, whereas human stroke usually occurs during the pathophysiological progression of underlying diseases or risk factors. Patients at risk for stroke are those with the comorbid conditions, including hyperlipidemia, obesity, diabetes mellitus, and hypertension. Therefore, Stroke Therapy Academic Industry Roundtable criterion for preclinical stroke evolution recommends determining the mechanisms and response to treatment in animal models with comorbid conditions, such as hyperlipidemia, diet-induced obesity, hypertension that adequately mimics the human scenario. 15 In the present study, we have implemented several Stroke Therapy Academic Industry Roundtable-RIGOR guidelines including (1) utilizing 2 different models for experimental stroke, with preexisting comorbidity (hyperlipidemia), (2) predefined inclusion-exclusion criteria, (3) conducting experiments in cohorts and blind fashion, (4) using both males and females, and (5) assessment of neurological outcome measures up to 1 week on the same mouse. Utilizing novel mutant strains, we provide genetic evidence that cellular Fn-EDA in the plasma, but not in the endothelial cells, contributes to the stroke exacerbation in the setting of comorbid hyperlipidemia. We found that lack of cellular Fn-EDA in the plasma significantly reduced infarct volume, improves poststroke survival and sensorimotor recovery by reducing thrombo-inflammatory responses.
Several studies suggest that activated endothelial cells synthesize and secrete Fn-EDA. 23, 24 Moreover, polymorphonuclear neutrophils, which are known to contribute to stroke progression, were implicated in the modulation of the endothelial Fn (most likely Fn-EDA) synthesis. 14 These observations suggest that endothelial Fn-EDA may contribute to stroke evolution. Surprisingly, we found that Fn-EDA present in the endothelial cells was not essential for stroke exacerbation. The possibility that a threshold of endothelial-derived Fn-EDA is required in the plasma to exacerbate stroke outcome cannot be ruled out. Significantly increased plasma levels of Fn-EDA have been reported in patients with cardiovascular disorders, [7] [8] [9] and acute ischemic stroke. 25 Next, using laser speckle imaging that measures real-time CBF with high spatial and temporal resolution, we found that lack of Fn-EDA in the plasma improves postreperfusion regional CBF in the core region. Improved regional CBF was associated with significantly reduced platelet thrombi and fibrin deposition. These results are in agreement with previous studies that have suggested a prothrombotic role for plasma Fn-EDA, which was mediated by platelet TLR4. 5, 28, 29 Platelets are known to have molecular machinery that is necessary for downstream signaling of TLR4, including components of the canonical NF-κB pathway. 30 Notably, Fn-EDA was associated with increased clot density in patients with type 2 diabetes mellitus favoring a prothrombotic state. 31 This study also identified that Fn-EDA specifically in the plasma promotes postischemic inflammation. We found that lack of Fn-EDA in the plasma reduces neutrophil influx that was associated with decreased expression of phospho-NFκB and inflammatory cytokines TNFα and IL-1β in the infarcted and surrounding region. Fn-EDA is an endogenous ligand for TLR4 32 and known to promote inflammation via TLR4 expressed on hematopoietic cells in experimental models. 5, 6 Together our data suggests that Fn-EDA in the plasma exacerbates stroke outcome by promoting postischemic thrombosis and vascular inflammation.
There is currently no effective intervention to reduce brain damage after reperfusion with r-tPA. A particular strength of this study is that targeting Fn-EDA specifically in the plasma improved stroke outcome followed by reperfusion with r-tPA in the comorbid condition of hyperlipidemia. A limitation of this study is that we did not confirm these findings in another species or with other preexisting comorbidities, including hypertension and aging. Extending these studies to large-animal models with preexisting comorbidities will be required to validate the translational feasibility of our current findings. In summary, our studies unequivocally support a causal connection between Fn-EDA present in the plasma and stroke exacerbation. These observations suggest that interventions targeting plasma Fn-EDA may reduce brain damage after reperfusion with r-tPA in humans.
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